BriaCell Therapeutics Corporation (BCTXW) ニュース

BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients

FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

BriaCell Therapeutics Announces Closing of $8.5 Million Offering

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 12, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell Therapeutics Announces $8.5 Million Offering

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

Form 8-K - Current report

BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer

Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune...

BriaCell Announces Positive Pre-IND Meeting with FDA for Bria-PROS+™ for Prostate Cancer

BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting...

BriaCell Announces Presentation at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell Quadruples Progression Free Survival (PFS) in Patient with “Eye-Bulging” Metastatic Breast Cancer

Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

BriaCell Presents Clinical Efficacy Data at ASCO 2024

BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the...

BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study

Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced...